

IAP20 Rec'd PCT/PTO 27 MAR 2006

SEQUENCE LISTING

<110> Bayer AG, BHC

<120> Diagnostics and Therapeutics for Diseases Associated with Arginyl Aminopeptidase RNPEP (RNPEP)

<130> Le A 36 899

<160> 5

<170> PatentIn version 3.1

<210> 1

<211> 2400

<212> DNA

<213> Homo sapiens

<400> 1

cacgaggcca	tggcgagccgg	cgagcattecc	ccccgcagcg	cgccggcccg	cgccgcgtgc	60
actccgcgca	ggctgcggcc	gctgaactcc	gcgcaggctg	tggacgtggc	ctcgccctcc	120
aacttccggg	cctttgagct	gctgacttg	cacctggacc	tcggggctga	gttcgggct	180
ccagggcccg	gcgcaggag	ccggggctg	agcggcaccc	cggtcctgga	cctgcgcgtgc	240
ctggagcccg	agggcgccgc	cgagctgcgg	ctggactcgc	acccgtgcct	ggaggtgacg	300
gcggcggcgc	tgcggcgaaa	geggccggc	tcggaggagc	cgccctgcgg	gcccgtgagc	360
ttctacacgc	agcccttctc	gcactatggc	caggccctgt	gcgtgtcctt	cccgcagccc	420
tgccgcgcgc	ccagggctg	ctcacctacc	gcgtcgaaa	gggacccccc	480	
gtttgctggg	tggctcccg	gcagacagca	ggaaagaaga	agcccttcgt	gtacacccag	540
ggccaggctg	tcctaaaccg	ggccttctc	ccttgcctcg	acacgcctgc	tgtaaaatac	600
aagtatttcg	ctcttatg	ggtcccagat	ggcttcacag	ctgtgtatg	tgcaagacat	660
ggggagaaga	gagggtccaaa	taagtttcc	ttccagatgt	gtcagccat	ccccctctat	720
ctgatagctt	tggccatcg	agatctggtt	tcggctgaag	ttggacccag	gagccgggtg	780
tgggctgagc	cctgcctgt	tgtgtcgcc	aaggagtaca	acgggggtat	agaagaattt	840
ttggcaacag	gagagaagct	ttttggacct	tatgtttggg	gaaggatgt	cttgccttc	900
atgccaccgt	cctttccatt	tggagaatg	gagaaccctt	gtctgacatt	tgtcaccccc	960
tgcctgctag	ctggggaccg	ctccttggca	gatgtcatca	tccatgagat	ctccccacagt	1020
tggtttggga	acctggtcac	caacgcaac	tgggtgaat	tctggctcaa	tgaaggtttc	1080
accatgtacg	cccagaggag	gatctccacc	atctctttg	gcgtcggt	cacctgctg	1140
gaggctgcaa	cggggcgccc	tctgcgtcg	caacacatgg	acatcaactgg	agaggaaaac	1200
ccactcaaca	agctccgcgt	gaagattgaa	ccaggcggt	acccggacga	cacctataat	1260
gagacccct	acgagaaaagg	tttctgtttt	gtctcatacc	tggcccactt	gttgggtgat	1320
caggatcagt	ttgacagttt	tctcaaggcc	tatgtgcgt	aattcaaatt	ccgaagcatc	1380
ttagccgatg	actttctgga	ttctacttg	gaatattcc	ctgagctaa	aaaaagaga	1440

Leu Ala Asp Asp Phe Leu Asp Phe Tyr Leu Glu Tyr Phe Pro Glu Leu
165 170 175
Lys Lys Lys Arg Val Asp Ile Ile Pro Gly Phe Glu Phe Asp Arg Trp
180 185 190
Leu Asn Thr Pro Gly Trp Pro Pro Tyr Leu Pro Asp Leu Ser Pro Gly
195 200 205
Asp Ser Leu Met Lys Pro Ala Glu Glu Leu Ala Gln Leu Trp Ala Ala
210 215 220
Glu Glu Leu Asp Met Lys Ala Ile Glu Ala Val Ala Ile Ser Pro Trp
225 230 235 240
Lys Thr Tyr Gln Leu Val Tyr Phe Leu Asp Lys Ile Leu Gln Lys Ser
245 250 255
Pro Leu Pro Pro Gly Asn Val Lys Lys Leu Gly Asp Thr Tyr Pro Ser
260 265 270
Ile Ser Asn Ala Arg Asn Ala Glu Leu Arg Leu Arg Trp Gly Gln Ile
275 280 285
Val Leu Lys Asn Asp His Gln Glu Asp Phe Trp Lys Val Lys Glu Phe
290 295 300
Leu His Asn Gln Gly Lys Gln Lys Tyr Thr Leu Pro Leu Tyr His Ala
305 310 315 320
Met Met Gly Gly Ser Glu Val Ala Gln Thr Leu Ala Lys Glu Thr Phe
325 330 335
Ala Ser Thr Ala Ser Gln Leu His Ser Asn Val Val Asn Tyr Val Gln
340 345 350
Gln Ile Val Ala Pro Lys Gly Ser
355 360

<210> 3
<211> 21
<212> DNA
<213> artificial sequence

<220>
<223> forward primer

<400> 3
gaagattgaa ccaggcggtt g a

21

<210> 4
<211> 25
<212> DNA
<213> artificial sequence

<220>

<223> reverse primer

<400> 4

ggtatgagac aaagcagaaa ccttt

25

<210> 5

<211> 30

<212> DNA

<213> artificial sequence

<220>

<223> probe

<400> 5

ccggacgaca cctataatga gaccccctac

30